A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen–progestogen treatment
| Autor: | L Skoog, B. von Schoultz, W Kersemaekers, M Mol-Arts, Kjell Carlström, Gunnar Söderqvist, Peter Conner, E Tani, A Christow |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Norpregnenes medicine.drug_class medicine.medical_treatment Urology Tibolone Placebo Sex hormone-binding globulin Double-Blind Method Estrogen Receptor Modulators medicine Humans Breast Prospective Studies Prospective cohort study Aged Gynecology Estradiol biology Progestogen business.industry Biopsy Needle Estrogen Replacement Therapy Antibodies Monoclonal Obstetrics and Gynecology Hormone replacement therapy (menopause) General Medicine Middle Aged Contraceptives Oral Synthetic Norethisterone acetate Norethindrone Acetate Ki-67 Antigen Estrogen biology.protein Female Norethindrone business Cell Division medicine.drug |
| Zdroj: | Climacteric. 7:50-58 |
| ISSN: | 1473-0804 1369-7137 |
| Popis: | To use the fine-needle aspiration (FNA) biopsy technique to compare the effects of tibolone, conventional hormone replacement therapy (HRT) and placebo on breast cell proliferation in postmenopausal women.A total of 91 women were randomized to receive either estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA), tibolone 2.5 mg or placebo for 6 months in a prospective double-blind trial. Breast cell proliferation was assessed using the Ki-67/MIB-1 monoclonal antibody.From the 83 women who completed the study, a total of 166 FNA biopsies were obtained, and 118 of these aspirates (71%) were evaluable for MIB-1 content. Women with assessable biopsies were younger, had a lower body mass index, and had higher levels of sex hormone binding globulin and insulin-like growth factor-I than women in whom the cell yield was insufficient. During treatment with E2/NETA, there was an increase in proliferation (percentage of MIB-1) from a mean value of 2.2 to 6.4% after 6 months (p0.01). No significant changes were recorded during treatment with tibolone or placebo. There was a negative association between proliferation and serum levels of total (r(s) = -0.29, p0.05) and free (rs = -0.31, p0.03) testosterone.Tibolone seems to have little influence on breast cell proliferation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|